학술논문
SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Document Type
Abstract
Author
Source
In Annals of Oncology June 2023 34 Supplement 1:S168-S168
Subject
Language
ISSN
0923-7534